论文部分内容阅读
目的：对比观察环磷酰胺、西艾克、阿霉素、顺铂（ＣＶＡＤ）与环磷酰胺、卡铂、足叶乙甙（ＣＣＥ）两方案治疗肺癌的疗效。方法：应用ＣＶＡＤ与ＣＣＥ两种联合化疗方案治疗５６例肺癌，观察疗效和毒性反应，并采用两样本比较的秩和检验或χ２检验。结果：ＣＶＡＤ方案和ＣＣＥ方案对肺癌的总有效率分别为６５％及４４％（Ｐ＞０．０５）。其中，对小细胞肺癌的有效数分别为８／９及５／７；对非小细胞肺癌的有效率分别为５５％及３３％（Ｐ＞０．０５）。ＣＶＡＤ方案对于初治和复治肺癌患者的有效率与ＣＣＥ方案差异均无显著性（Ｐ＞０．０５）；而恶心、呕吐、脱发、静脉炎等发生率ＣＶＡＤ方案高于ＣＣＥ方案（Ｐ＜０．０５～Ｐ＜０．０１）。结论：两方案对于初治肺癌患者均可选用。
OBJECTIVE: To compare the efficacy of cyclophosphamide, cyacillin, doxorubicin, cisplatin (CVAD) and cyclophosphamide, carboplatin, and acetylcholine (CCE) in the treatment of lung cancer. Methods: 56 cases of lung cancer were treated with CVAD and CCE combined chemotherapy. The efficacy and toxicity were observed and the two-sample comparison of rank sum test or chi-square test was used. Results: The total effective rates of CVAD and CCE regimens for lung cancer were 65% and 44%, respectively (P>0.05). Among them, the effective numbers for small cell lung cancer were 8/9 and 5/7, respectively; the effective rates for non-small cell lung cancer were 55% and 33%, respectively (P>0.05). There was no significant difference between the CVAD regimen and the CCE regimen in the efficacy and CCE regimen of naïve and retreatment lung cancer patients. The incidence of nausea, vomiting, hair loss and phlebitis was higher in the CVAD regimen than in the CCE regimen (P< 0.05-P<0.01). Conclusion: Both options can be used for primary lung cancer patients.